Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-12-13
2005-12-13
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S252160
Reexamination Certificate
active
06974837
ABSTRACT:
Pharmaceutical compositions and dosage forms are disclosed that comprise a racemic or optically pure sibutramine metabolite and a phosphodiesterase inhibitor.
REFERENCES:
patent: 3155669 (1964-11-01), Janssen et al.
patent: 3155670 (1964-11-01), Janssen et al.
patent: 3471515 (1969-10-01), Troxler et al.
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3960891 (1976-06-01), Malen et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4522828 (1985-06-01), Jeffery et al.
patent: 4552828 (1985-11-01), Toya et al.
patent: 4746680 (1988-05-01), Jeffery et al.
patent: 4806570 (1989-02-01), Jeffery et al.
patent: 4814352 (1989-03-01), Jeffery et al.
patent: 4816488 (1989-03-01), Rees
patent: 4871774 (1989-10-01), Rees
patent: 4929629 (1990-05-01), Jeffery
patent: 4939175 (1990-07-01), Ukai et al.
patent: 4988814 (1991-01-01), Abou-Gharbia et al.
patent: 5059595 (1991-10-01), Le Grazie
patent: 5068440 (1991-11-01), Jeffery et al.
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5104899 (1992-04-01), Young et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5250534 (1993-10-01), Bell et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5436272 (1995-07-01), Scheinbaum
patent: 5459164 (1995-10-01), Vargas
patent: 5552429 (1996-09-01), Wong et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5674553 (1997-10-01), Shinoda et al.
patent: 5719283 (1998-02-01), Bell et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5780051 (1998-07-01), Eswara et al.
patent: 5795880 (1998-08-01), Svec et al.
patent: 6046242 (2000-04-01), Emmelmann
patent: 6127363 (2000-10-01), Doherty, Jr. et al.
patent: 6174925 (2001-01-01), Bailey et al.
patent: 2002/0006963 (2002-01-01), Young et al.
patent: 2002/0006964 (2002-01-01), Young et al.
patent: 0 035 597 (1981-09-01), None
patent: 0 781 561 (1997-07-01), None
patent: 2098602 (1982-11-01), None
patent: WO 88/06444 (1988-09-01), None
patent: WO 90/06110 (1990-06-01), None
patent: WO 94/00047 (1994-01-01), None
patent: WO 94/00114 (1994-01-01), None
patent: WO 94/28902 (1994-12-01), None
patent: WO 95/20949 (1995-08-01), None
patent: WO 95/21615 (1995-08-01), None
patent: WO 97/03675 (1997-02-01), None
patent: WO 97/20810 (1997-06-01), None
patent: WO 98/06722 (1998-02-01), None
patent: WO 98/11884 (1998-03-01), None
patent: WO 98/13033 (1998-04-01), None
patent: WO 98/13034 (1998-04-01), None
patent: WO 00/32182 (1998-11-01), None
patent: WO 99/33450 (1999-07-01), None
patent: WO 00/54765 (2000-09-01), None
patent: WO 00/56148 (2000-09-01), None
patent: WO 00/56149 (2000-09-01), None
patent: WO 00/56150 (2000-09-01), None
patent: WO 00/56161 (2000-09-01), None
patent: WO 00/56306 (2000-09-01), None
patent: WO 00/56309 (2000-09-01), None
patent: WO 00/56314 (2000-09-01), None
patent: WO 00/56315 (2000-09-01), None
patent: WO 00/56318 (2000-09-01), None
patent: WO 00/56321 (2000-09-01), None
patent: WO 00/56322 (2000-09-01), None
Baldessarini et al.,Life Sciences39: 1765-1777, (1986).
Buckett et al., “BTS 54 524-An Approach to Rapidly Acting Antidepressant,”New Concepts in Depression2: 167-172 (1988).
Bucket et al., “The Pharmacology of Sibutramine Hydrochloride (BTS 54 524), A New Antidepressant which induces Rapid Noradrenergic Down-Regulation”,Prog. Neuro-Psychopharmacol.&Biol. Psychiat.12:575-584 (1988).
Buckett et al., “Sibutramine Hydrochloride,”Drugs of the Future13(8): 736-738 (1988).
Butler, D.,Facile Cycloalkylation of Arylacetonitriles in Dimethyl Sulfoxide,J. Org. Chem., 36:1308-1309 (1971).
Canonne, P., et al.,Effet du Benzene Dans la Reaction de Grignard sur les Nitriles,Tetrahedron Lett., 21:155-58 (1980).
Carstensen, J.,Drug Stability: Principles&Practice,2d Ed., pp. 379-380, Marcel Dekker, NY, NY, (1995).
Castello, R.A., et al.,Discoloration of Tablets Containing Amines and Lactose,Pharm. Sci. 51(2):106-108 (1962).
Cheetham, S.C. et al.,[3H]Paroxetine Binding in Rat Frontal Cortex Strongly Correlates with [3H]5-HT Uptake: Effect of Administration of Various Antidepressant Treatments,Neuropharmacology (1993), 32(8), 737-743.
Cliffe et al., (S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: A Selective Antagonist at Presynaptic and Postsynaptic 5-HT1AReceptors, Med. Chem., 36:1509-1510 (1993).
Diagnostic and Statistical Manual of Mental Disorders,Fourth Ed., American Psychiatric Association, (1997).
Diagnostic and Statistical Manual of Mental Disorders,3rd Ed., American Psychiatric Association (1981).
Dreshfield et al.,Enhancement of Fluoxetine-Dependent Increase of Extracellular Serotonin(5-HT)Levels by(−)-Pindolol, an Antagonist at 5-HT1AReceptors,Neurochem. Res., 21(5):557-562 (1996).
Eliel, E.L.,Stereochemistry of Carbon Compounds(McGraw-Hill, NY, 1962).
Evans et al., “Prevalence of Alzheimer's Disease in a Community Population of Older Persons,”J.A.M.A.262: 2551-2556 (1989).
Fuentes, J.et al., “Comparison of the apparent anti-depressant activity of (−) and (+) tranylpromine in an animal model”,Chemical Abstracts,85: 7, p. 31, No. 40768t (1976).
Goodman & Gilman, The Pharmacological Basis of Therapeutics, 362-373, 404 (9thed. McGraw-Hill, 1996).
Gray et al.,The involvement of the Opioidergic System in the Antinociceptive Mechanism of Action of Antidepressant Compounds,BR.J. Pharmacol., vol. 124, No. 4, (1998) pp 669-674.
Handbook of Pharmaceutical Excipients, 2nded., Wade and Willer eds., pp. 257-259 (1994).
Heal et al.,A Comparison of the Effects of Central 5-HT Function of Sibutramine Hydrochloride and Other Weight-Modifying Agents,BR.J. Pharmacol. (1998), 125(2), 301-308.
Hillver et al., (S)-5-Fluoro-8-hydroxy-2-(dipropylamino)tetralix: A Putative 5-HT1AReceptor Antagonist,J. Med. Chem., 33:1541-44 (1990).
J. Med. Chem., vol. 36, No. 17, 2540 (1993).
Introduction to Pharmaceutical Dosage Forms,4th ed., Lea & Febiger, Philadelphia (1985).
Jacques et al., “Enantiomers, Racemates and Resolutions,” (Wiley-Interscience, NY, 1981).
Jamali et al.,Journal of Pharmaceutical Sciences,78: 9: 695-715 (1989).
Jeffery et al.,Synthesis of Sibutramine, A Novel Cyclobutylalkylamine Useful in the Treatment of Obesity, and its Major Human Metabolites,J. Chem. Soc. Perkin. Trans. 1, 2583-2589 (1996).
King et al., “Clinical Pharmacology of Sibutramine Hydrochloride (BTS 54524) A New Antidepressant, in Healthy Volunteers,”Clinical Pharmac.26: 607-611 (1989).
Kula et al., “Effects of N-Substituted Phenyltetrahydropyridines on Cerebral High-Affinity Synatosomal Uptake of Dopamine and Other Monoamines in Several Mammalian Species,” Life Sciences34(26): 2567-2575, (1984).
Luscombe et al.,The Contribution of Metabolites to the Rapid and Potent Down-Regulation of Rat Cortical β-Adrenoceptors by the Putative Antidepressant Sibutramine Hydrochloride,Neuropharmacology, vol. 28, No. 2, (1989) pp 129-134.
The Merck Manual of Diagnosis and Therapy, ??th Ed., Merck & Co., Inc., Whitehouse Station, NJ, (1999).
Middlemiss et al.,Centrally Active 5-HT Receptor Agonists and Antagonists,Neurosci. and Biobehv. Rev., 16:75-82 (1992).
Moreau et al.,Behavioral Profile of the 5-HT1AReceptor Antagonist(S)-UH-301 in Rodents and Monkeys,Brain Res. Bull., 29:901-04 (1992).
Nakada et al.,An Enantioconvergent Route to(−)-Kainic Acid,Tetrahedron Lett., 38:857-860 (1997).
Physician's Desk Reference® 473-475 (53rded., 1999).
Physician's Desk Reference® 475-476 (53rded., 1999).
Physician's Desk Reference® 764-766 (53rded., 1999).
Physician's Desk Reference® 823-825 (53rded., 1999).
Physician's Desk Reference® 978-979 (53rded., 1999).
Physician's Desk Reference® 1054-1056 (53rded., 1999).
Physician's Desk Reference® 1332-1334 (53rded., 1999).
Physician's Desk Reference® 1369-1370 (53rded., 1999).
Physician's Desk Reference® 1432-1436 (53rded.
Fang Qun K.
Jerussi Thomas P.
Senanayake Chrisantha H.
Jones Day
Sepracor Inc.
Spivack Phyllis G.
LandOfFree
Compositions comprising sibutramine metabolites in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions comprising sibutramine metabolites in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions comprising sibutramine metabolites in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3500162